Countdown to West Pharmaceutical (WST) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

Wall Street analysts forecast that West Pharmaceutical Services (WST) will report quarterly earnings of $1.83 per share in its upcoming release, pointing to a year-over-year increase of 0.6%. It is anticipated that revenues will amount to $794.26 million, exhibiting an increase of 6.1% compared to the year-ago quarter.

Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

With that in mind, let's delve into the average projections of some West Pharmaceutical metrics that are commonly tracked and projected by analysts on Wall Street.

Analysts predict that the 'Net Sales- Contract-Manufactured Products' will reach $144.45 million. The estimate points to a change of +7.1% from the year-ago quarter.

According to the collective judgment of analysts, 'Net Sales- Proprietary Products' should come in at $648.56 million. The estimate points to a change of +5.7% from the year-ago quarter.

Analysts forecast 'Change in Organic Revenue' to reach 1.8%. The estimate is in contrast to the year-ago figure of 3.3%.

The collective assessment of analysts points to an estimated 'Gross Profit- Proprietary Products' of $257.16 million. The estimate is in contrast to the year-ago figure of $250.70 million.

The consensus estimate for 'Gross Profit- Contract-Manufactured Products' stands at $25.76 million. The estimate compares to the year-ago value of $22.90 million.

Shares of West Pharmaceutical have demonstrated returns of -8.8% over the past month compared to the Zacks S&P 500 composite's no change. With a Zacks Rank #2 (Buy), WST is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Just Released: Zacks Top 10 Stocks for 2026

Hurry – you can still get in early on our 10 top tickers for 2026. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful.

From inception in 2012 through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.

Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2026. You can still be among the first to see these just-released stocks with enormous potential.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research